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FOREWORD: ANTI-ANGIOGENIC THERAPY: MAXIMIZING
THERAPEUTIC GAIN
Adam P. Dicker, MD, PHD
Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College
of Thomas Jefferson University, Philadelphia, PA
On June 25, 2004, the Radiation Therapy Oncology Group (RTOG, www.rtog.org) held a
symposium, “Anti-Angiogenic Therapy: Maximizing Therapeutic Gain,” in Washington,
D.C., in conjunction with the RTOG’s semi-annual meeting.
The symposium brought together a diverse group of clinicians and basic scientists,
leading experts in the field, to foster the development of innovative research in
multicenter cooperative group projects. The topics covered were the following: role of
angiogenesis in normal tissue biology and cancer cell biology, mechanism of action in
tumor-growth inhibition of selective anti-angiogenic inhibitors, effects of anti-angiogenic
inhibitors on preclinical tumor models alone and in combination with cytotoxic
chemotherapy and radiation therapy, issues regarding clinical trial design using novel
agents, and the results of clinical trials using inhibitors of angiogenesis alone or in
combination with radiation or chemotherapy.
I would like to acknowledge the advice and support of Dr. Walter Curran, Jr., chairman
of the RTOG, and Tom Wudarski and Sharon Hartson Stine, who provided logistical
support and help with visual materials. I would also like to acknowledge the helpful
feedback and counsel of members of the Translational Research Program, including Drs.
Luka Milas and Paul Okunieff.
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